Jefferies making positive comments; Reiterates Buy rating, price target raised to $53 from $46 #
- Company expects to submit their CTA for UCART19 for a PI trial in ALL/CLL in the UK in '15 (trial to begin in Q4). CLLS will file its IND for a PI trial in US in '16.
- Firm believes CLLS offers a unique approach to developing CAR-T therapy by using gene-editing techniques which may allow for "off-the-shelf" CAR-T.